Skip to main content

Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics.

Publication ,  Journal Article
Huneault, HE; Gent, AE; Cohen, CC; He, Z; Jarrell, ZR; Kamaleswaran, R; Vos, MB
Published in: Hepatol Commun
March 1, 2024

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, is the most common liver disease in children. Liver biopsy remains the gold standard for diagnosis, although more efficient screening methods are needed. We previously developed a novel NAFLD screening panel in youth using machine learning applied to high-resolution metabolomics and clinical phenotype data. Our objective was to validate this panel in a separate cohort, which consisted of a combined cross-sectional sample of 161 children with stored frozen samples (75% male, 12.8±2.6 years of age, body mass index 31.0±7.0 kg/m2, 81% with MASLD, 58% Hispanic race/ethnicity). METHODS: Clinical data were collected from all children, and high-resolution metabolomics was performed using their fasting serum samples. MASLD was assessed by MRI-proton density fat fraction or liver biopsy and cardiometabolic factors. Our previously developed panel included waist circumference, triglycerides, whole-body insulin sensitivity index, 3 amino acids, 2 phospholipids, dihydrothymine, and 2 unknowns. To improve feasibility, a simplified version without the unknowns was utilized in the present study. Since the panel was modified, the data were split into training (67%) and test (33%) sets to assess the validity of the panel. RESULTS: Our present highest-performing modified model, with 4 clinical variables and 8 metabolomics features, achieved an AUROC of 0.92, 95% sensitivity, and 80% specificity for detecting MASLD in the test set. CONCLUSIONS: Therefore, this panel has promising potential for use as a screening tool for MASLD in youth.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hepatol Commun

DOI

EISSN

2471-254X

Publication Date

March 1, 2024

Volume

8

Issue

3

Location

United States

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Metabolomics
  • Male
  • Humans
  • Female
  • Cross-Sectional Studies
  • Child
  • Biopsy
  • Antifibrinolytic Agents
  • Adolescent
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huneault, H. E., Gent, A. E., Cohen, C. C., He, Z., Jarrell, Z. R., Kamaleswaran, R., & Vos, M. B. (2024). Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics. Hepatol Commun, 8(3). https://doi.org/10.1097/HC9.0000000000000375
Huneault, Helaina E., Alasdair E. Gent, Catherine C. Cohen, Zhulin He, Zachery R. Jarrell, Rishikesan Kamaleswaran, and Miriam B. Vos. “Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics.Hepatol Commun 8, no. 3 (March 1, 2024). https://doi.org/10.1097/HC9.0000000000000375.
Huneault HE, Gent AE, Cohen CC, He Z, Jarrell ZR, Kamaleswaran R, et al. Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics. Hepatol Commun. 2024 Mar 1;8(3).
Huneault, Helaina E., et al. “Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics.Hepatol Commun, vol. 8, no. 3, Mar. 2024. Pubmed, doi:10.1097/HC9.0000000000000375.
Huneault HE, Gent AE, Cohen CC, He Z, Jarrell ZR, Kamaleswaran R, Vos MB. Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics. Hepatol Commun. 2024 Mar 1;8(3).

Published In

Hepatol Commun

DOI

EISSN

2471-254X

Publication Date

March 1, 2024

Volume

8

Issue

3

Location

United States

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Metabolomics
  • Male
  • Humans
  • Female
  • Cross-Sectional Studies
  • Child
  • Biopsy
  • Antifibrinolytic Agents
  • Adolescent